Last edition
News about "Tirzepatide"
US FDA Proposes Excluding Semaglutide, Tirzepatide and Liraglutide from 503B Bulks List
The US Food and Drug Administration (FDA) proposes excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, citing no clinical need for compounding these GLP-1 drugs by outsourcing facilities.
Tirzepatide | 04/05/2026 | By News Bureau
PrecisionLife and Ovation Partner to Launch GLP-1 stratification LDT and GLP-1 DNA Test in H2 2026
PrecisionLife and Ovation partner to launch GLP-1 stratification LDT and consumer DNA test in 2026, with early data showing distinct genetic markers for weight loss and glycemic control.
Tirzepatide | 16/04/2026 | By News Bureau
Vanda Pharmaceuticals Launches Thetis Study to Test NEREUS for GLP-1 Agonist-Induced Vomiting
Vanda Pharmaceuticals launches Thetis study, a multicenter clinical trial testing NEREUS (oral tradipitant) to prevent vomiting in patients starting high-dose GLP-1 receptor agonists, evaluating safety and efficacy.
Tirzepatide | 09/04/2026 | By News Bureau | 171
LillyDirect and Walmart Pharmacy Launch Retail Pick-Up for Zepbound at DTC Pricing
Walmart, with nearly 4,600 pharmacies nationwide, will serve as the first in-store pickup pharmacy for LillyDirect's self-pay single-dose vials.
Tirzepatide | 30/10/2025 | By Dineshwori | 447
Eli Lilly And Cipla Partner to Distribute Yurpeak (Tirzepatide) in India
Eli Lilly and Cipla have signed an agreement to distribute and promote tirzepatide in India under a second brand name, Yurpeak.
Tirzepatide | 27/10/2025 | By Dineshwori | 573
Wegovy (Semaglutide 2.4 mg) reduced risk of heart attack, stroke, or death by 57 percent when compared to Tirzepatide, and 29 percent across all patients, showing heart-protective benefits unique to the Semaglutide molecule.
Tirzepatide | 19/09/2025 | By Dineshwori | 241
Wegovy Outperforms Tirzepatide, Slashes Cardiovascular Risk by 57 Percent
Wegovy showed a significant 29 percent risk reduction for heart attack, stroke and death from any cause compared with Tirzepatide (over an average follow-up of 8.3 months for Wegovy and 8.6 months for Tirzepatide.
Tirzepatide | 01/09/2025 | By Dineshwori | 175
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy